Senior Vice President, Head of Research, Development and Medical Affairs (RDMA)Sobi, Basel, SwitzerlandBasel, Basel-Stadt, Switzerland
OC 50.2 - Long-term outcomes with efanesoctocog alfa prophylaxis for previously treated children with severe hemophilia A, an interim analysis of the phase 3 XTEND-ed study
Tuesday, June 25, 202409:45 – 10:00 ICT
